Effect of intestinal microbiota imbalance associated with chronic hepatitis B virus infection on the expression of microRNA‑192 and GLP‑1

Liu,Yinghui

doi:10.3892/mmr.2021.12301

Effect of intestinal microbiota imbalance associated with chronic hepatitis B virus infection on the expression of microRNA‑192 and GLP‑1

Authors:
- Yinghui Liu
View Affiliations

Affiliations: Department of Infectious Disease, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China
Published online on: July 19, 2021 https://doi.org/10.3892/mmr.2021.12301
Article Number: 662

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been reported that hepatitis B virus (HBV) infection has an impact on intestinal microbiota imbalance to induce diabetes mellitus (DM), but the underlying mechanisms still remain to be explored. The present study aimed to investigate the regulatory role of microRNA‑192 (miR‑192‑5p) and glucagon‑like peptide‑1 (GLP‑1) in intestinal microbiota imbalance by recruiting patients with DM infected with HBV. In the present study, patients with HBV infection and different levels of alanine transaminase (ALT) were recruited and divided into three groups. Intestinal microbiota analysis was performed to evaluate the fecal bacterial composition of patients in various groups. Quantitative PCR was performed to explore the differential expression of miR‑192‑5p and GLP‑1 in the feces, peripheral blood and intestinal mucosal tissue samples of each patient. Immunohistochemistry was used to assess the expression of GLP‑1 protein in the intestinal mucosal tissue samples. Luciferase assays were performed by cell transfection of miR‑192‑5p mimics/precursors/inhibitors to study the inhibitory effect of miR‑192‑5p on GLP‑1 expression. Intestinal microbiota imbalance was observed in hepatitis B surface antigen (HBsAg)‑positive patients with high ALT. The expression of miR‑192‑5p was significantly elevated in the feces, peripheral blood and intestinal mucosal tissue samples of HBsAg‑positive patients with high ALT along with decreased GLP‑1 mRNA and protein expression. Luciferase activity of GLP‑1 vector was inhibited by miR‑192‑5p mimics and promoted by miR‑192‑5p inhibitors. Transfection of miR‑192‑5p precursors resulted in upregulation of miR‑192‑5p and downregulation of GLP‑1, while miR‑192‑5p inhibitors remarkably suppressed the expression of miR‑192‑5p and notably induced the expression of GLP‑1. These results showed a regulatory network involving HBV infection, intestinal microbiota imbalance, and miR‑192‑5p and GLP‑1 expression.

View Figures

View References

1	Beasley RP: Rocks along the road to the control of HBV and HCC. Ann Epidemiol. 19:231–234. 2009. View Article : Google Scholar : PubMed/NCBI
2	Cho EJ, Kim SE, Suk KT, An J, Jeong SW, Chung WJ and Kim YJ: Current status and strategies for hepatitis B control in Korea. Clin Mol Hepatol. 23:205–211. 2017. View Article : Google Scholar : PubMed/NCBI
3	Younossi Z, Kochems K, de Ridder M, Curran D, Bunge EM and de Moerlooze L: Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. Hum Vaccin Immunother. 13:2695–2706. 2017. View Article : Google Scholar : PubMed/NCBI
4	Szabo G and Bala S: Alcoholic liver disease and the gut-liver axis. World J Gastroenterol. 16:1321–1329. 2010. View Article : Google Scholar : PubMed/NCBI
5	Zhang D, Hao X, Xu L, Cui J, Xue L and Tian Z: Intestinal flora imbalance promotes alcohol-induced liver fibrosis by the TGFβ/smad signaling pathway in mice. Oncol Lett. 14:4511–4516. 2017. View Article : Google Scholar : PubMed/NCBI
6	Mou H, Yang F, Zhou J and Bao C: Correlation of liver function with intestinal flora, vitamin deficiency and IL-17A in patients with liver cirrhosis. Exp Ther Med. 16:4082–4088. 2018.PubMed/NCBI
7	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
8	Fisher K and Lin J: MicroRNA in inflammatory bowel disease: Translational research and clinical implication. World J Gastroenterol. 21:12274–12282. 2015. View Article : Google Scholar : PubMed/NCBI
9	Peck BC, Weiser M, Lee SE, Gipson GR, Iyer VB, Sartor RB, Herfarth HH, Long MD, Hansen JJ, Isaacs KL, et al: MicroRNAs classify different disease behavior phenotypes of crohn's disease and may have prognostic utility. Inflamm Bowel Dis. 21:2178–2187. 2015. View Article : Google Scholar : PubMed/NCBI
10	Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J, Zhu J, Xing C and Xu H: microRNA-192, −194 and −215 are frequently downregulated in colorectal cancer. Exp Ther Med. 3:560–566. 2012. View Article : Google Scholar : PubMed/NCBI
11	Jones MF, Hara T, Francis P, Li XL, Bilke S, Zhu Y, Pineda M, Subramanian M, Bodmer WF and Lal A: The CDX1-microRNA-215 axis regulates colorectal cancer stem cell differentiation. Proc Natl Acad Sci USA. 112:E1550–E1558. 2015. View Article : Google Scholar : PubMed/NCBI
12	Fischer J, Walker LC, Robinson BA, Frizelle FA, Church JM and Eglinton TW: Clinical implications of the genetics of sporadic colorectal cancer. ANZ J Surg. 89:1224–1229. 2019. View Article : Google Scholar : PubMed/NCBI
13	Moloney GM, Viola MF, Hoban AE, Dinan TG and Cryan JF: Faecal microRNAs: Indicators of imbalance at the host-microbe interface? Benef Microbes. 9:175–183. 2018. View Article : Google Scholar : PubMed/NCBI
14	Dalmasso G, Nguyen HT, Yan Y, Laroui H, Charania MA, Ayyadurai S, Sitaraman SV and Merlin D: Microbiota modulate host gene expression via microRNAs. PLoS One. 6:e192932011. View Article : Google Scholar : PubMed/NCBI
15	Liu S, da Cunha AP, Rezende RM, Cialic R, Wei Z, Bry L, Comstock LE, Gandhi R and Weiner HL: The host shapes the gut Microbiota via fecal MicroRNA. Cell Host Microbe. 19:32–43. 2016. View Article : Google Scholar : PubMed/NCBI
16	Pan W, Zhang Y, Zeng C, Xu F, Yan J and Weng J: miR-192 is upregulated in T1DM, regulates pancreatic β-cell development and inhibits insulin secretion through suppressing GLP-1 expression. Exp Ther Med. 16:2717–2724. 2018.PubMed/NCBI
17	Yun Y, Chang Y, Kim HN, Ryu S, Kwon MJ, Cho YK, Kim HL, Cheong HS and Joo EJ: Alterations of the gut microbiome in chronic hepatitis B virus infection associated with alanine aminotransferase level. J Clin Med. 8:1732019. View Article : Google Scholar : PubMed/NCBI
18	Lin PY, Chen SC, Lo TC and Kuo HW: Dual infection with hepatitis B virus and hepatitis C virus correlated with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 128:38–42. 2020. View Article : Google Scholar : PubMed/NCBI
19	Xie QH, He XX, Chang Y, Jiang X and Lin JS: HBx gene down-regulates miR-192 expression and inhibits apoptosis of human hepatoma cell line HepG2. Zhonghua Gan Zang Bing Za Zhi. 19:857–860. 2011.(In Chinese). PubMed/NCBI
20	Yuan X, Ni H, Chen X, Feng X, Wu Q and Chen J: Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora. J Cell Biochem. 119:10067–10074. 2018. View Article : Google Scholar : PubMed/NCBI
21	Shin EC, Sung PS and Park SH: Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 16:509–523. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ou JH: Molecular biology of hepatitis B virus e antigen. J Gastroenterol Hepatol. 12:S178–S187. 1997. View Article : Google Scholar : PubMed/NCBI
23	Ben Q, Li Z, Liu C, Cai Q, Yuan Y, Wang K, Xiao L, Gao J and Zhang H: Hepatitis B virus status and risk of pancreatic ductal adenocarcinoma: A case-control study from China. Pancreas. 41:435–440. 2012. View Article : Google Scholar : PubMed/NCBI
24	Li YT, Wang L, Chen Y, Chen YB, Wang HY, Wu ZW and Li LJ: Effects of gut microflora on hepatic damage after acute liver injury in rats. J Trauma. 68:76–83. 2010.PubMed/NCBI
25	Neelam K, Goenadi CJ, Lun K, Yip CC and Au Eong KG: Putative protective role of lutein and zeaxanthin in diabetic retinopathy. Br J Ophthalmol. 101:551–558. 2017. View Article : Google Scholar : PubMed/NCBI
26	Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J and Bandres E: miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther. 9:2265–2275. 2010. View Article : Google Scholar : PubMed/NCBI
27	Hu F, Meng X, Tong Q, Liang L, Xiang R, Zhu T and Yang S: BMP-6 inhibits cell proliferation by targeting microRNA-192 in breast cancer. Biochim Biophys Acta. 1832:2379–2390. 2013. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:e050052015. View Article : Google Scholar : PubMed/NCBI
30	Hutin YJ, Bulterys M and Hirnschall GO: How far are we from viral hepatitis elimination service coverage targets? J Int AIDS Soc. 21 (Suppl 2):e250502018. View Article : Google Scholar : PubMed/NCBI
31	Milich D and Liang TJ: Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 38:1075–1086. 2003. View Article : Google Scholar : PubMed/NCBI
32	Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, Girgis H, Von Both I, Bjarnason GA and Yousef GM: miR-192, miR-194 and miR-215: A convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis. 34:2231–2239. 2013. View Article : Google Scholar : PubMed/NCBI
33	Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B and Kinzler KW: Gene expression profiles in normal and cancer cells. Science. 276:1268–1272. 1997. View Article : Google Scholar : PubMed/NCBI
34	Rashid H, Hossain B, Siddiqua T, Kabir M, Noor Z, Ahmed M and Haque R: Fecal microRNAs as potential biomarkers for screening and diagnosis of intestinal diseases. Front Mol Biosci. 7:1812020. View Article : Google Scholar : PubMed/NCBI
35	Sarshar M, Scribano D, Ambrosi C, Palamara AT and Masotti A: Fecal microRNAs as innovative biomarkers of intestinal diseases and effective players in host-microbiome interactions. Cancers (Basel). 12:21742020. View Article : Google Scholar : PubMed/NCBI
36	Honda K and Littman DR: The microbiome in infectious disease and inflammation. Annu Rev Immunol. 30:759–795. 2012. View Article : Google Scholar : PubMed/NCBI
37	Kim M and Zhang X: The profiling and role of miRNAs in diabetes mellitus. J Diabetes Clin Res. 1:5–23. 2019.PubMed/NCBI
38	Holst JJ, Vilsboll T and Deacon CF: The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 297:127–136. 2009. View Article : Google Scholar : PubMed/NCBI
39	Kieffer TJ and Habener JF: The glucagon-like peptides. Endocr Rev. 20:876–913. 1999. View Article : Google Scholar : PubMed/NCBI
40	Flint A, Raben A, Astrup A and Holst JJ: Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 101:515–520. 1998. View Article : Google Scholar : PubMed/NCBI
41	Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, Long SJ, Morgan LM, Holst JJ and Astrup A: A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 86:4382–4389. 2001. View Article : Google Scholar : PubMed/NCBI
42	Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H and Skibicka KP: The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: A new role for mesolimbic GLP-1 receptors. J Neurosci. 32:4812–4820. 2012. View Article : Google Scholar : PubMed/NCBI
43	Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, et al: Repeated intracerebroventricular administration of glucagon-like peptide-1-(7–36) amide or exendin-(9–39) alters body weight in the rat. Endocrinology. 140:244–250. 1999. View Article : Google Scholar : PubMed/NCBI